Clinical-stage biopharmaceutical company Compugen announced on Monday that it will report its second quarter financial results before the U.S. market opens on Monday, August 3, 2026. Company management will host a conference call to discuss the results and answer questions from analysts.

Compugen is a biopharmaceutical firm focused on developing cancer immunotherapy, with a core pipeline including monoclonal and bispecific antibodies targeting novel immune checkpoints, aiming to provide new treatment options for patients with solid tumors.

Market expectations are that Compugen's second quarter revenue will primarily come from milestone payments and research service revenue from its pharmaceutical partners, estimated to be between $1 million and $3 million. As the company remains in the clinical development stage with no approved products yet, analysts are closely focused on the clinical progress of its lead candidate drugs, the advancement of its collaboration programs, and its cash burn rate.

Compugen recently announced that patient enrollment is nearing completion for a Phase II clinical trial of its leading candidate, COM701 (an antibody targeting PVRIG) in combination with a PD-1 inhibitor. Preliminary data from this trial is expected to be released in the second half of 2026. Investors are hoping to gain more details about this trial and the company's timeline for releasing the full dataset during the upcoming earnings call.

The company currently holds approximately $120 million in cash and cash equivalents and expects its existing funds to be sufficient to support operations through 2028. Analysts will be watching to see if the company adjusts its estimates for annual R&D spending and operational cash burn.

Compugen's earnings conference call is scheduled for 8:30 a.m. Eastern Time on August 3. Investors can listen to a live webcast via the Investor Relations section of the company's website.